Affymetrix has launched its benchtop GeneAtlas system for gene expression analysis.
GeneAtlas is based on a new array strip format that allows users to interrogate four samples simultaneously. Array strips are currently available for expression profiling of the human, mouse, and rat genomes, the company said.
The array strip is also available for custom array designs through Affy's MyGeneChip program. The company said that it will introduce additional arrays and applications in the future.
The company said that GeneAtlas combines its gene expression technology "with the simplest workflow available and an unprecedented price," but did not disclose pricing for the system.
The system includes all required instrumentation, training materials, and data analysis programs. The platform is designed "to meet the needs of researchers with no microarray experience," as well as low- to medium-throughput service laboratories, educational laboratories, and emerging markets, Affy said.
Febit this week launched an updated version of its Geniom Biochip for cancer research. The new chip contains 58 newly discovered sequences in addition to all of the Homo sapiens microRNAs from miRBase version 14, the company said.
The 58 new miRNA sequences were found by high-throughput sequencing in an miRNA discovery study performed on an Applied Biosystems SOLiD 3 sequencing system. The new miRNAs were validated using the ABI TaqMan miRNA qRT-PCR assay. ABI is a business of Life Technologies.
Asterand, a provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery, this week launched Good Laboratory Practice-compliant molecular pathology services supporting preclinical safety studies.
The company now offers tissue cross-reactivity testing for therapeutic antibodies in order to supply clients with data required by regulatory authorities in the US and the EU. In addition to installing a GLP-compliant laboratory, Asterand said it is also offering a frozen tissue microarray platform for the pre-screening of therapeutic antibody candidates prior to full GLP-compliant studies.
Roche NimbleGen said last week that it has certified Berlin-based genomics services company ImaGenes to offer its DNA methylation analysis arrays.
ImaGenes passed the certification to become a certified service provider for the DNA methylation analysis workflow, which is used in identifying novel genetic markers that can be used in diagnostic and prognostic development programs.
In December 2009, Roche certified ImaGenes to offer NimbleGen microarrays for chromatin immunoprecipitation-on- array services. The certification makes ImaGenes the first NimbleGen service provider in Europe with multiple certifications, Roche said.